The Salk Institute for Biological Studies

Mitobridge, Inc.

The University of Sydney

Other

Ligand Pharmaceuticals, Inc.

Baylor College of Medicine

Sloan-kettering Institute for Cancer Research

New York University

The United States of America

Howard Hughes Medical Institute

The Government of the United States of America

Ronald Mark Evans

Michael Downes

Ruth T Yu

Annette R Atkins

Estelita S Ong

Vincent Giguere

Kazuhiko Umesono

Barry M Forman

David John Mangelsdorf

Jae Myoung Suh

Cary Alan Weinberger

Catherine C Thompson

Stanley M Hollenberg

Richard Alan Heyman

Anthony E Oro

Christopher Liddle

Thomas J Baiga

Arthur F Kluge

Marcus F Boehm

John F W Keana

Bruce Blumberg

Johan W Jonker

Gregor Eichele

Jeffrey Arriza

Prudimar S Segui

Tso-Pang Yao

Christina Thaller

Michael A Patane

Joseph Noel

Bharat Lagu

Masanori Miura

Taisuke Takahashi

Sunil Kumar Panigrahi

Ramesh Senaiar

Eiji Yoshihara

Susanta Samajdar

Takashi Ishikawa

Michael G Rosenfeld

Fumimaro Takaku

Michio Imawari

Laszlo Nagy

Sungsoon Fang

J Don Chen

Henry M Sucov

Mark G Bock

Enrique Saez

Peter Tontonoz

Ye Zheng

Steven A Kliewer

Uwe K Borgmeyer

Emi Kanakubo Embler

Zong Wei

Weiwei Fan

William A Segraves

Mike A Patane

Sagar P Bapat

Jean E Rivier

Wylie W Vale, Jr

Marianne Bowman

Christina S Berger

Robert B Stein

Ning Ding

Nanthakumar Subramaniam

Michael B Mc Keown

Vihang A Narkar

Mark A Verdicia

Lindsey J Bowman

Wen Xie

Yasuyuki Kida

Peter Ordentlich

Teruhisa Kawamura

Bruce M Spiegelman

Kenneth R Chien

Moosa Mohammadi

Regina Goetz

Joseph R Ecker

Joachim Spiess

Marvin R Brown

Ralph L Brinster

Richard D Palmiter

Senyon Choe

Reuben J Shaw

John Fw Keana

Patricia J Willy

Authur F Kluge

Sihao Liu

David No

Richard J Lin

Emiliana Borrelli

Hung-Ying Kao

Witek Kwiatkowski

Mara Sherman

Vassilis Doucas

Ryan Lister

Caroline Flora Samer

Kazuhiko Uemsono

Toshihiko Ogura

Klaus Damm

Ronald Schule

Margaret A Harmon

The invention features compositions and methods treating or preventing for age-related insulin resistance, type 2 diabetes and related disorders. The method involves depleting fTreg cells with an anti-ST2 antibody to decrease age-related fTreg accumulation and restore insulin sensitivity, thereby treating age-related insulin resistance, type 2 diabetes and related disorders.

Compositions and methods for treating age-related diabetes and related disorders

The invention features compositions comprising in vitro generated beta cells capable of glucose-stimulated insulin secretion, methods of inducing beta cell maturation from embryonic or induced pluripotent stem cell-derived beta-like cells, and methods of using in vitro generated beta cells for the treatment of type 1 diabetes, type 2 diabetes, or a related disorder.

Compositions and methods for treating type 1 and type 2 diabetes and related disorders

The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency.

Reprogramming progenitor compositions and methods of use thereof

The invention features pancreatic islet and pancreatic organoids, and cell cultures and methods that are useful for the rapid and reliable generation of pancreatic islet and pancreatic islet organoids. The invention also features methods of treating pancreatic diseases and methods of identifying agents that are useful for treatment of pancreatic diseases, such as type 2 diabetes and pancreatic cancer, using the pancreatic islet and pancreatic organoids of the invention.

Compositions and methods for organoid generation and disease modeling

Provided herein are compounds and compositions useful in increasing PPAR&#x3b4; activity. The compounds and compositions provided herein are useful for the treatment of PPAR&#x3b4; related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof

The present disclosure provides FGF1 mutant proteins, which selectively bind to/activate FGFR1b. Also provided are nucleic acid molecules that encode such proteins, and vectors and cells that include such nucleic acids. Methods of using the disclosed FGF1 mutants to reduce blood glucose in a mammal and treat a metabolic disorder are provided.

Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose

Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

Analogs of fexaramine and methods of making and using

PPAR agonists

Methods are provided for reducing blood glucose, which utilize an agent that increases the biological activity of a vitamin D receptor (VDR) (e.g., a VDR agonist), in combination with an antagonist of bromodomain-containing protein 9 (BRD9). IN some examples, such methods treat type II diabetes.

Use of bromodomain-containing protein 9 antagonists in combination with vitamin D receptor agonists in diabetes treatment

Provided herein are deuterated compounds and compositions useful in increasing PPAR&#x3b4; activity. The compounds have a formula where Lcomprises at least one deuterium. Exemplary species include The compounds and compositions provided herein are useful for the treatment of PPAR&#x3b4; related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

PPAR agonists and methods of use thereof

The invention generally features compositions comprising induced pluripotent stem cell progenitors (also termed reprogramming progenitor cells) and methods of isolating such cells. The invention also provides compositions comprising induced pluripotent stem cells (iPSCs) derived from such progenitor cells. Induced pluripotent stem cell progenitors generate iPSCs at high efficiency. In particular embodiments the invention is predicated upon increased expression of an estrogen related receptor and changes in the oxidative and glycolytic pathways.

Reprogramming progenitor compositions and methods of use therefore

Growing community of inventors

La Jolla, CA, United States of America

Ronald Mark Evans